ATyr Pharma Stock Sinks, Plans FDA Review After Mixed Phase 3 Results
Biotech firm aTyr Pharma Inc. (NASDAQ:ATYR) plummeted over 81% at last check on Monday, with a session volume of 34.7 million compared to the average volume of 4.83 million as per data from Benzinga Pro.
Benzinga ·